VNDA
Vanda Pharmaceuticals
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Vanda Pharmaceuticals received European Commission Orphan designation for imsidolimab for generalized pustular psoriasisAug 24, 2026
- Vanda receives positive EMA opinion for orphan drug designation of Imsidolimab for generalized pustular psoriasisJul 19, 2026
- Vanda Pharmaceuticals received FDA Rare Pediatric Disease Designation for its investigational therapy for Charcot-Marie-Tooth disease type 2SJul 8, 2026
- Vanda Pharmaceuticals announced the U.S. commercial launch of NEREUS for motion sicknessMay 4, 2026
- Vanda initiated Thetis trial evaluating NEREUS for preventing GLP-1-induced vomitingApr 9, 2026